Moriya et al., 1996 - Google Patents
In VivoInhibition of Hepatitis B Virus Gene Expression by Antisense Phosphorothioate OligonucleotidesMoriya et al., 1996
- Document ID
- 13465746442813651364
- Author
- Moriya K
- Matsukura M
- Kurokawa K
- Koike K
- Publication year
- Publication venue
- Biochemical and biophysical research communications
External Links
Snippet
While an important goal of treatment for hepatitis B is to prevent the development of hepatocellular carcinoma, there has been no effective therapy for it. Antisense oligodeoxynucleotide treatment could in principle inhibit hepatitis B virus gene expression …
- 230000014509 gene expression 0 title abstract description 41
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Moriya et al. | In VivoInhibition of Hepatitis B Virus Gene Expression by Antisense Phosphorothioate Oligonucleotides | |
JP4709545B2 (en) | Modified small interfering RNA molecules and methods of use | |
Goodarzi et al. | Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen | |
EP2270162B1 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
Nie et al. | Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis | |
US6107028A (en) | Ribozymes for treating hepatitis C | |
US10982212B2 (en) | Conserved HBV and HCV sequences useful for gene silencing | |
EP0759979A1 (en) | Antisense inhibition of hepatitis c virus | |
DE69626393T2 (en) | SPECIFIC OLIGONUCLEOTIDS FOR HEPATITIS B VIRUS | |
US20030119017A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of IKK-gamma and PKR | |
JP2004532022A (en) | Oligonucleotide-mediated inhibition of hepatitis B virus and hepatitis C virus replication | |
JP2012223202A (en) | Conserved hbv and hcv sequences useful for gene silencing | |
WO1994024864A1 (en) | Methods of preventing viral replication | |
Goodarzi et al. | Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice | |
JP2003525037A (en) | Methods and reagents for regulation and diagnosis of CD20 and NOGO gene expression | |
US20040127446A1 (en) | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication | |
US20040054156A1 (en) | Method and reagent for inhibiting hepatitis B viral replication | |
US20030171311A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection | |
US20020177568A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B | |
US20030068301A1 (en) | Method and reagent for inhibiting hepatitis B virus replication | |
Cherney et al. | Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo | |
Hsieh et al. | Delta virus as a vector for the delivery of biologically-active RNAs: possibly a ribozyme specific for chronic hepatitis B virus infection | |
US20030140362A1 (en) | In vivo models for screening inhibitors of hepatitis B virus | |
US20030125270A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection | |
US20030073207A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |